Market Views – Page 16 – media

NOVO HOLDINGS LAUNCHES USD 165M IMPACT FUND TO COMBAT ANTIMICROBIAL RESISTANCE

Antimicrobial resistance is a global threat to human health. Novo Holdings today announces the launch of an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
- Source: novonordiskfonden.dk
- 477
- March 7, 2018
Antimicrobial resistance Market Views
Four health systems and VA plan to create nonprofit drug company

Four health systems — Intermountain Healthcare, Ascension, SSM Health and Trinity Health — and the U.S. Department of Veterans Affairs will launch a nonprofit generic drug company.
- Source: Medcitynews
- 419
- March 7, 2018
generic drug Market Views
Market for 3D-printed medical devices to cross $2 bn by 2025

The global market for 3D printing of medical devices is estimated to touch $2.77 billion by 2015, according to a new study by market research and investment information firm Profshare Market Research.
- Source: TechCircle
- 410
- March 7, 2018
3D printing Market Views medical device products
TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®) and TESARO’s PARP-inhibitor ZEJULA® (niraparib) in patients with metastatic bladder cancer.
- Source: ir.tesarobio
- 795
- March 6, 2018
antibody bladder cancer Market Views oncology
Finch Therapeutics Raises $36 Million Series B, Bringing Total to $77 Million

Finch Therapeutics, headquartered in Somerville, Massachusetts, closed on an oversubscribed Series B financing worth $36 million. Since the company’s launch, it has raised $77 million. Series B investors included Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital.
- Source: Biospace
- 575
- March 6, 2018
Market Views microbiome Series
Healthcare execs say EHRs don’t do enough to manage value-based contracts

Healthcare providers are increasingly looking to EHRs and third-party population health management solutions to help them with value-based care.
- Source: Healthcare Dive
- 578
- March 6, 2018
digital health EHR health IT Market Views
Qualcomm Life signs deal with AlertWatch, PeriGen

Qualcomm Life announced an exclusive licensing agreement with AlertWatch, creator of an FDA-cleared intelligence care software that assists in the care of patients in the operating room. The deal will give Qualcomm Life the exclusive rights to sell AlertWatch, which the company plans to showcase at HIMSS 2018.
- Source: MobiHealthNews
- 582
- March 2, 2018
digital health FDA Market Views
Generation Bio Raises $100 Million to Advance Re-Dosable Gene Therapy

Generation Bio said it closed a $100 million series B financing to advance to the clinic its first two therapeutics candidates using its GeneWave platform to develop a new class of genetic medicines with drug-like qualities.
- Source: globalgenes.org
- 509
- March 2, 2018
genetic medicine Market Views Series
Viela Bio Spins Out of MedImmune; Raises Up to $250 Million in Series A Financing, 6 Dimensions Capital Leads Investment

Viela Bio announced today that it has incorporated as an independent, inflammation - and autoimmunity - focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca. Viela Bio will primarily focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of the diseases.
- Source: finance.yahoo
- 483
- March 1, 2018
autoimmunity inflammation Market Views
Navigating the Legal Complexities of a Digital Health Transaction

Whatever the long-term future for life sciences, in house lawyers and their business counterparts as well as outside advisors who are able to navigate the convergence of business and legal issues surrounding the life sciences and technology industries will have a competitive advantage over those who ignore the parallel convergences that are taking place, continuing to focus instead on life sciences and technology as distinct and separate fields.
- Source: Corporate Council - Law.com
- 545
- March 1, 2018
big data digital health healthcare technologies and innovations Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.